首页 > 市场调查报告书 > 製药

消化器

市场调查报告书

商品编码

1477257

胃动力障碍药物市场，按疾病类型，按药物类别，按配销通路，按地理位置

Gastric Motility Disorder Drug Market, By Disorder Type, By Drug Class, By Distribution Channel, By Geography

出版日期: 2024年04月03日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年胃动力障碍药物市场价值为576.5亿美元，预计到2031年将达到831.5亿美元，2024年至2031年的年复合成长率（CAGR）为5.4%。

报告范围		报告详情
基准年：	2023年	2024 年市场规模：	576.5 亿美元
历史数据：	2019年至2023年	预测期：	2024年至2031年
预测 2024 年至 2031 年复合年增长率：	5.40%	2031 年价值预测：	831.5 亿美元

图 1. 2024 年胃动力障碍药物市场占有率 (%)（按地区）

胃动力障碍是指胃需要比平常更多或更少的时间来排空其内容物的疾病。一些常见的胃动力障碍包括胃轻瘫和功能性消化不良。当胃中的肌肉运动缓慢或紊乱，导致食物在胃中滞留的时间比正常情况更长时，就会发生胃轻瘫。它会影响正常的消化过程，并经常引起噁心、腹胀和呕吐。同样，功能性消化不良涉及胃排空过程受损，导致上腹部不适。在许多情况下，胃动力障碍的确切原因尚不清楚；然而，它们可能是由于迷走神经损伤、糖尿病、某些药物、手术或其他潜在的健康状况而引起的。目前用于胃动力障碍的药物疗法包括旨在刺激胃动力并加速胃排空的促动力剂。鑑于此类疾病的慢性性质且缺乏彻底治癒方法，全球胃动力药物市场预计将在未来几年稳定成长。

市场动态：

全球胃动力药物市场受到糖尿病盛行率不断上升的推动，因为糖尿病是胃轻瘫的高风险因素。与胃动力障碍相关的住院时间延长和工作效率下降也导致了他们日益沉重的经济负担。预计这将刺激对更有效药物疗法的需求。然而，由于缺乏针对某些类型胃动力障碍的核准药物，市场潜力受到限制。此外，与现有药物选择相关的副作用构成了重大挑战。开发具有更好安全性的新型药物配方可以在这个市场上带来利润丰厚的机会。采用联合疗法和开发针对未满足需求的特定区域配方是一些关键机会。

研究的主要特点：

该报告对全球胃动力障碍药物市场进行了深入分析，并提供了预测期（2024-2031）的市场规模（十亿美元）和年复合成长率（CAGR%），以2023年为基准年。
它阐明了不同细分市场的潜在收入成长机会，并解释了该市场有吸引力的投资主张矩阵。
这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
它根据以下参数描述了全球胃动力障碍药物市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球胃动力障碍药物市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
利害关係人可以透过用于分析全球胃动力障碍药物市场的各种策略矩阵轻鬆做出决策。

介绍
北美洲
我们
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地区
欧洲
英国
德国
义大利
法国
西班牙
俄罗斯
欧洲其他地区
亚太地区
中国
印度
日本
东协
澳洲
韩国
亚太地区其他地区
中东
海湾合作委员会
以色列
中东其他地区
非洲
北非
中非
南非

第 9 章：竞争格局

公司简介
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Janssen Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Boehringer Ingelheim
- Eli Lilly and Company
- Bristol Myers Squibb
- Daiichi Sankyo Company, Limited
- Bausch Health Companies
- Mallinckrodt Pharmaceuticals
- Endo Pharmaceuticals
- Eisai Co., Ltd.
- Ferring Pharmaceuticals
- UCB
- Evoke Pharma
- Cadila Pharmaceuticals

第 10 章：分析师观点

命运之轮
分析师观点
连贯的机会图

第 11 章：参考文献与研究方法

参考
研究方法论

简介目录

Product Code: CMI6849

The gastric motility disorder drug market is estimated to be valued at USD 57.65 Bn in 2024 and is expected to reach USD 83.15 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 57.65 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	5.40%	2031 Value Projection:	US$ 83.15 Bn

Figure 1. Gastric Motility Disorder Drug Market Share (%), By Region, 2024

Gastric Motility Disorder Drug Market - IMG1

Gastric motility disorder refers to conditions wherein the stomach takes more or less time than usual to empty its contents. Some common gastric motility disorders include gastroparesis and functional dyspepsia. Gastroparesis occurs when the muscle movements in the stomach are either sluggish or disordered, causing food to get stuck in the stomach for a longer duration than normal. It affects the normal digestive process and often causes nausea, bloating, and vomiting. Similarly, functional dyspepsia involves impaired gastric emptying processes leading to discomfort in the upper abdomen. The exact causes of gastric motility disorders are unknown in many cases; however, they may arise due to damage to the vagus nerve, diabetes, certain medications, surgery, or other underlying health conditions. Currently available drug therapies for gastric motility disorders include prokinetics that aim to stimulate gastric motility and hasten gastric emptying. Given the chronic nature and lack of complete cure for such disorders, the global gastric motility drug market is poised to grow steadily in the coming years.

Market Dynamics:

The global gastric motility drug market is driven by the increasing prevalence of diabetes as it is a high-risk factor for gastroparesis. Extended hospital stays and loss of work productivity associated with gastric motility disorders also contribute to their growing economic burden. This is anticipated to fuel the demand for more effective drug therapies. However, the market potential is restricted by the lack of approved drugs for some types of gastric motility disorders. Moreover, side effects associated with existing drug options pose a major challenge. Development of novel drug formulations with better safety profiles can present lucrative opportunities in this market. Adoption of combination therapies and development of region-specific formulations tailored to address the unmet needs are some key opportunities.

Key Features of the Study:

This report provides an in-depth analysis of the global gastric motility disorder drug market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global gastric motility disorder drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global gastric motility disorder drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gastric motility disorder drug market.

Detailed Segmentation-

Disorder Type:
- Upper Digestive Tract
- Achalasia
- Gastroesophageal Reflux Disease (GERD)
- Gastroparesis
- Dumping Syndrome
- Lower Digestive Tract
- Intestinal Pseudo-obstruction
- Small Intestinal Bacterial Overgrowth (SIBO)
- Pelvic Dyssynergia
- Hirschsprung's Disease
Drug Class:
- Antacids
- Antidiarrheals
- Calcium-channel Blockers
- H2 Blockers
- Proton Pump Inhibitors
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Janssen Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Boehringer Ingelheim
- Eli Lilly and Company
- Bristol Myers Squibb
- Daiichi Sankyo Company, Limited
- Bausch Health Companies
- Mallinckrodt Pharmaceuticals
- Endo Pharmaceuticals
- Eisai Co., Ltd.
- Ferring Pharmaceuticals
- UCB
- Evoke Pharma
- Cadila Pharmaceuticals

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Disorder Type
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
Pricing Analysis
PEST Analysis

4. Global Gastric Motility Disorder Drug Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 impact on the market

5. Global Gastric Motility Disorder Drug Market, By Disorder Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Upper Digestive Tract
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Achalasia
Gastroesophageal Reflux Disease (GERD)
Gastroparesis
Dumping Syndrome
Lower Digestive Tract
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Intestinal Pseudo-obstruction
Small Intestinal Bacterial Overgrowth (SIBO)
Pelvic Dyssynergia
Hirschsprung's Disease

6. Global Gastric Motility Disorder Drug Market, By Drug Class, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Antacids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Antidiarrheals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Calcium-channel Blockers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
H2 Blockers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Proton Pump Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Gastric Motility Disorder Drug Market, By Distribution Channel, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Gastric Motility Disorder Drug Market, By Region, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disorder Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Pfizer Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Takeda Pharmaceutical Company Limited
- Janssen Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Boehringer Ingelheim
- Eli Lilly and Company
- Bristol Myers Squibb
- Daiichi Sankyo Company, Limited
- Bausch Health Companies
- Mallinckrodt Pharmaceuticals
- Endo Pharmaceuticals
- Eisai Co., Ltd.
- Ferring Pharmaceuticals
- UCB
- Evoke Pharma
- Cadila Pharmaceuticals